Latest patent covers bilateral hematoma detection and disposable lightguides for patient interface

 InfraScan, a medical device firm specializing in brain injury diagnostic products, announced today the issuance to it by the US Patent Office of an additional patent that covers the brain hematoma detection technology.

The patent for invention number 8,060,189 is for a system and method for detection of hematoma.

"This latest patent makes claims in connection with our technology that allows removable and disposable fiber optic lightguides for interface with the blood covered heads of brain injury victims" said Baruch Ben Dor, PhD, president and CEO of InfraScan. "It further covers a method for detection of bilateral hematomas, which expands our technology platform portfolio." he said.

The patent covers the technology in InfraScan's Infrascanner™, a hand-held, point-of-care device to detect bleeding in traumatic brain injury. It further covers the Infrascanner technology to communicate its output either via wired or wireless interface.

The latest patent is the twelfth in the USA to cover the Infrascanner method, system and the disposable patient interface caps. The Infrascanner technology is also covered by 20 international patents, exclusively licensed to InfraScan. InfraScan has nearly 150 devices deployed internationally, including with some of the world's leading Neurotrauma experts. InfraScan also licensed a variety of patents that apply to hemorrhagic and ischemic stroke detection.

In the general population, an estimated 1.5 million individuals seek medical treatment for head trauma in the U.S. each year, and a total of 10 million individuals seek head trauma treatment annually worldwide. The Infrascanner has obtained its CE mark, European marketing clearance, and is now being marketed in Russia, Italy, Romania, Poland, Bulgaria, Hungary, Saudi Arabia, Panama, Greece, Turkey and India. Further sales and marketing networks are being established in additional countries and regions. The company has conducted a pivotal multicenter study in the U.S. and has made a DeNovo application to the U.S. FDA. The product is currently under review with FDA.

About InfraScan – InfraScan, Inc. is a medical device company that focuses on developing, commercializing and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technologies. The company has received early-stage funding from the U.S. Marine Corps, Office of Naval Research, BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and from the Philadelphia Industrial Development Corporation. For more information visit http://www.infrascanner.com.